Head-to-head evidence
ASC30 vs CT-996
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
ASC30
Developed by Ascletis Pharma
NCT07002905 · Phase 2 · completed
The study randomly assigned 125 participants and used quadruple blinding with placebo control across seven cohorts. Its primary endpoint was percent change in body weight at Week 13, but the registry has not posted whether this endpoint was met.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: July 2028 · NCT07743450 (registry estimate)
CT-996
Developed by Roche
NCT07081958 · Phase 2 · completed
The study randomized 352 participants to placebo or one of seven RO7795081 dosing regimens, with participants and investigators blinded. Its primary endpoint was the clinical measure of percent change in body weight at Week 30, but no results or statistical comparison have been posted, so the endpoint cannot yet be classified as met or missed.
Next expected readout: December 2026 · NCT06982131 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ASC30's landscape · CT-996's landscape